Peijia Medical sees strong revenue growth in 2024

Peijia Medical Limited (HKEX: 9996) announced unaudited operating statistics for the year ended December 31, 2024, revealing a substantial revenue increase to approximately RMB 610.0-630.0 million, compared to RMB 441.1 million in 2023, representing a growth of 38.3% to 42.8%. The company attributes this growth to strong performance across its neurointerventional product lines and an expanding share in the Chinese transcatheter aortic valve replacement (TAVR) market. Specifically, the success of products like DCwire® Micro Guidewire and the continued adoption of its coil products contributed significantly. Additionally, over 150 new hospitals adopted TaurusOne® and TaurusElite® TAVR products, leading to over 3,400 units implanted during the year, with TAVR products now covering nearly 650 hospitals cumulatively. The company is finalizing its annual results, which are expected to be published in March 2025.